Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:43:39.092Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:43:39.092Z.
Quote observation: 2026-10-06T16:40:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
FORWARD PE RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$214.85M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $214.85M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 18.69 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $213.50M | N/A |
| Alector, Inc. (ALEC)vs › | $217.34M | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $218.46M | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $209.50M | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.02M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $222.26M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $205.93M | 20.87 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
